Gilead Beats 4Q, but suffers…for now

photo credit: Prescription Prices Ver5 via photopin (license)
photo credit: Prescription Prices Ver5 via photopin (license)

 

Gilead surprised us. A Dividend. $2.43 a share earnings on $6.67 billion revenue. Net sales between $26-$27 billion. And a $15 billion share repurchase program.

All of this is good news.

But, they also announced that they were severely discounting Harvoni, their miraculous Hep C drug, by as much as 50%.

Although it is a pricey, but effective drug, we remain positive that this discount will open up more doors. Making it cheaper and more available, we feel, will make it accessible to more people.